Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

Pile of research papers

The living reviews will summarise literature around one topic and are a response to the speed and volume of COVID-19 immunology research published during the pandemic.

On behalf of the Oxford-Cardiff COVID-19 Literature Consortium, Dr Ewoud Compeer, University of Oxford points out the idea behind this new publishing format: "The field of COVID-19 immunology was seeing new developments and new hypotheses appearing at an extreme pace online in the form of pre-prints. This speed of publishing made literature reviews outdated even before a journal published them. Our 'living reviews' will stay "live" for a designated period, being updated as change happens."

The journal publishes peer reviewed scientific articles, and the annotation enables rapid communication of updated information, but the version of record does not change so provides a history of the scientific developments.

The full story is available on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.